Table 2.

Lipid profiles and platelet activation markers of patients with ACS at baseline and 72 h post-evolocumab administration.

	Baseline (n = 31)	Evolocumab (n = 31)	P -value
TG (mg/dL)	152.4 [113.4, 217.1]	129.4 [108.1, 170.1]	0.0082
TC (mg/dL)	194.1 [159.3, 221.9]	100.9 [71.91, 143.0]	<0.0001
HDL-C (mg/dL)	36.73 [32.86, 46.39]	36.73 [31.31, 44.07]	0.0868
LDL-C (mg/dL)	109.0 [90.85, 144.6]	41.37 [19.33, 69.97]	<0.0001
sdLDL-C (mg/dL)	34.02 [29.38, 52.19]	12.76 [8.119, 17.78]	<0.0001
ApoA1 (g/L)	1.23 [1.12, 1.39]	1.19 [1.05, 1.34]	0.0272
ApoB (g/L)	1.06 [0.92, 1.19]	0.51 [0.31, 0.72]	<0.0001
ApoE (g/L)	4.12 [3.30, 5.17]	2.36 [1.69, 3.18]	<0.0001
Soluble P-selectin (ng/mL)	26.03 [20.04, 33.06]	29.40 [24.60, 37.14]	0.2132
Platelet factor-4 (ng/mL)	1.38 [1.15, 1.65]	1.21 [0.81, 1.66]	0.1270

Data expressed as median (interquartile range). Differences were tested using Wilcoxon matched-pairs signed rank test.

TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; sdLDL-C, small dense low-density lipoprotein cholesterol; Apo, apolipoprotein.